Edition:
United Kingdom

Celldex Therapeutics Inc (CLDX.OQ)

CLDX.OQ on NASDAQ Stock Exchange Global Select Market

2.93USD
2:51pm GMT
Change (% chg)

$0.01 (+0.34%)
Prev Close
$2.92
Open
$2.92
Day's High
$2.93
Day's Low
$2.91
Volume
227,764
Avg. Vol
260,445
52-wk High
$4.07
52-wk Low
$2.20

Select another date:

Fri, Nov 17 2017

BRIEF-Celldex Therapeutics initiates phase 2 combination study of CDX-3379 and Cetuximab in head and neck squamous cell Carcinoma

* Celldex Therapeutics Inc initiates phase 2 combination study of CDX-3379 and Cetuximab in head and neck squamous cell Carcinoma Source text for Eikon: Further company coverage:

BRIEF-Celldex Therapeutics Q3 loss per share $0.20

* Q3 earnings per share view $-0.27 -- Thomson Reuters I/B/E/S

BRIEF-Celldex announces completion of enrollment in phase 2b study of Glembatumumab Vedotin in triple negative breast cancer

* Celldex announces completion of enrollment in phase 2b study of Glembatumumab Vedotin in triple negative breast cancer

BRIEF-Celldex Therapeutics Q2 loss per share $0.23

* Celldex Therapeutics - Q2 revenue $3.8 million versus $1.4 million

BRIEF-Celldex Therapeutics Q2 loss per share $0.23

* Q2 earnings per share view $-0.27 -- Thomson Reuters I/B/E/S Source text for Eikon: Further company coverage:

BRIEF-Celldex Therapeutics promotes Sam Martin as CFO

* Celldex Therapeutics announces additions to the board of directors and senior management team

Select another date: